Analytical interference in the therapeutic drug monitoring of methotrexate.

Fiche publication

Date publication

juin 2016

Journal

Annales de biologie clinique

Auteurs

Membres identifiés du Cancéropôle Est :
Dr OUDART Jean-Baptiste

Tous les auteurs :
Oudart JB, Marquet B, Feliu C, Gozalo C, Djerada Z, Millart H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27101631

Résumé

High-dose of methotrexate chemotherapy is used in the treatment of some tumors. It presents several side effects that required therapeutic drug monitoring, which is commonly performed on 24, 48 and 72h after the beginning of the methotrexate infusion. Treatment of overexposure to methotrexate is based on injection of carboxypeptidase G2, which specifically degrades methotrexate into inactive metabolite: DAMPA. FPIA immunoassay on TDx automated analyzer (Abbott™) was used for therapeutic drug monitoring of methotrexate. This immunoassay presented a significant cross-reactivity between methotrexate and DAMPA, which widely overestimate the residual concentration compared to the gold standard HPLC/MS. TDx automated analyzer was substituted by a new immunoassay on Architect automated analyzer (Abbott™). However, this immunoassay has the same cross-reactivity, which needs to be careful when monitoring methotrexate after an injection of carboxypeptidase G2. In order to determine the most suitable assay for the therapeutic drug monitoring of methotrexate, the knowledge of injection of carboxypeptidase G2 remains essential.